Moderna provides an update on regulatory submissions for RSV vaccine candidate, mRNA-1345

FHS
July 10, 2023
6:23 am

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update on regulatory submissions for mRNA-1345, a vaccine for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD) and acute respiratory disease (ARD) in adults aged 60 years or older.

Exclusive: How an accidental email tipped Pfizer off to an activist investor’s plan

The message over the weekend to Pfizer’s CEO Albert Bourla was blank. But it contained a warning nonetheless. It came from his former CFO Frank

October 11, 2024

Readers respond to H5N1 and livestock movements, insulin discontinuation, and more

To encourage robust, good-faith discussion about difficult issues, STAT publishes selected Letters to the Editor received in response to First Opinion essays. Submit a Letter

May 18, 2024

Analysis Reveals the Most Significant Improvements From Psychedelic Use Apply To Single Individuals | Psychedelic Invest

A recent analysis has revealed that individuals who have used psychedelics at some point in their lives experience lower levels of psychological distress. Interestingly, the

July 2, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.